Sinil Pharmaceutical Co., Ltd. (KOSDAQ: 012790)

Sinil Pharmaceutical Income Statement

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Operating Revenue	91,699	89,135	80,007	61,754	61,438	60,648
Other Revenue	-	-	-0	-	-	-
Revenue	91,699	89,135	80,007	61,754	61,438	60,648
Revenue Growth (YoY)	6.37%	11.41%	29.56%	0.51%	1.30%	13.84%
Cost of Revenue	51,673	51,565	44,362	37,313	37,234	35,773
Gross Profit	40,027	37,570	35,645	24,441	24,204	24,875
Selling, General & Admin	20,602	19,491	17,623	15,574	15,522	14,299
Research & Development	2,651	2,979	3,264	194.52	784.55	529.9
Other Operating Expenses	427.14	355.82	378.68	374.75	395.92	318.73
Operating Expenses	24,941	23,579	21,989	16,459	17,583	15,461
Operating Income	15,086	13,991	13,656	7,982	6,621	9,415
Interest Expense	-22.19	-26.13	-6.05	-9.72	-13.24	-216.82
Interest & Investment Income	1,080	849.37	352.84	184.48	224.04	426.73
Currency Exchange Gain (Loss)	11.59	-59.59	90.91	26.14	4.22	-0.77
Other Non Operating Income (Expenses)	1,243	1,379	899.91	14.64	1,226	-1,028
EBT Excluding Unusual Items	17,398	16,134	14,994	8,197	8,062	8,595
Gain (Loss) on Sale of Investments	-	-532.61	-478.44	115.48	-11.37	-15.66
Gain (Loss) on Sale of Assets	3.81	-641.55	221.3	14	13.42	-219.89
Asset Writedown	-7	-7	-92.08	14.5	97.5	-14.57
Pretax Income	17,395	14,953	14,645	8,341	8,162	8,345
Income Tax Expense	2,330	1,312	2,488	1,663	617.51	1,088
Net Income	15,066	13,641	12,157	6,679	7,544	7,257
Net Income to Common	15,066	13,641	12,157	6,679	7,544	7,257
Net Income Growth	19.34%	12.21%	82.02%	-11.47%	3.96%	27.01%
Shares Outstanding (Basic)	12	12	12	11	11	11
Shares Outstanding (Diluted)	12	12	12	11	11	11
Shares Change (YoY)	-0.12%	-0.04%	3.91%	-0.97%	-0.08%	-2.92%
EPS (Basic)	1303.47	1179.82	1051.00	600.00	671.15	645.07
EPS (Diluted)	1303.47	1179.82	1051.00	600.00	671.15	645.07
EPS Growth	19.48%	12.26%	75.17%	-10.60%	4.04%	30.83%
Free Cash Flow	22,398	1,551	3,336	7,820	2,261	2,576
Free Cash Flow Per Share	1937.87	134.13	288.44	702.52	201.11	228.96
Gross Margin	43.65%	42.15%	44.55%	39.58%	39.40%	41.02%
Operating Margin	16.45%	15.70%	17.07%	12.93%	10.78%	15.52%
Profit Margin	16.43%	15.30%	15.20%	10.82%	12.28%	11.97%
Free Cash Flow Margin	24.43%	1.74%	4.17%	12.66%	3.68%	4.25%
EBITDA	21,144	19,353	18,088	12,518	11,053	13,697
EBITDA Margin	23.06%	21.71%	22.61%	20.27%	17.99%	22.58%
D&A For EBITDA	6,059	5,361	4,432	4,536	4,432	4,282
EBIT	15,086	13,991	13,656	7,982	6,621	9,415
EBIT Margin	16.45%	15.70%	17.07%	12.93%	10.78%	15.52%
Effective Tax Rate	13.39%	8.77%	16.99%	19.93%	7.57%	13.04%
Advertising Expenses	-	1,059	762.13	157.25	206.15	266.98

Source: S&P Capital IQ. Standard template. Financial Sources.